Literature DB >> 27005594

Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma.

Judit Lazary1, Nora Eszlari2, Gabriella Juhasz3, Gyorgy Bagdy2.   

Abstract

Fatty acid amide hydrolase (FAAH) inhibitors are addressed for promising anxiolytics, but human studies on genetically reduced FAAH activity, stress and affective phenotypes are scarce. We investigated the effect of a functional polymorphism of FAAH (FAAH C385A or rs324420; low FAAH activity and high anandamide concentration are associated with the A allele) together with childhood adversity on the anxious and depressive phenotypes in 858 subjects from the general population. Phenotypes were measured by the Zung Self-Rating Depression Scale (ZSDS), the depression and anxiety subscales of the Brief Symptom Inventory (BSI-DEP, BSI-ANX) and the State-Trait Anxiety scales (STAI-S, STAI-T). Childhood Adversity Questionnaire (CHA) was used to assess early life traumas. Frequency of the A allele was greater among subjects with high ZSDS scores compared to the CC genotype. Furthermore, FAAH C385A and the CHA have shown a robust gene-environment interaction, namely, significantly higher anxiety and depression scores were exhibited by individuals carrying the A allele if they had high CHA scores compared to CC carriers. These data provided preliminary evidence that genetically reduced FAAH activity and repetitive stress in the childhood are associated with increased vulnerability for anxiety and depression in later life. Our results together with earlier experimental data suggest that permanently elevated anandamide level together with early life stress may cause a lifelong damage on stress response probably via the downregulation of CB1R during the neurodevelopment in the brain. It may also point to pharmacogenomic consequences, namely ineffectiveness or adverse effects of FAAH inhibitors in this subpopulation.
Copyright © 2016 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  CB1 receptor; Endocannabinoids; Epigenetics; Neurodevelopment; Personalized medicine; Pharmacogenomics

Mesh:

Substances:

Year:  2016        PMID: 27005594     DOI: 10.1016/j.euroneuro.2016.03.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  18 in total

1.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

Review 2.  Gene-Environment Interactions in Psychiatry: Recent Evidence and Clinical Implications.

Authors:  Rashelle J Musci; Jura L Augustinavicius; Heather Volk
Journal:  Curr Psychiatry Rep       Date:  2019-08-13       Impact factor: 5.285

3.  Constitutive Increases in Amygdalar Corticotropin-Releasing Factor and Fatty Acid Amide Hydrolase Drive an Anxious Phenotype.

Authors:  Luis A Natividad; Matthew W Buczynski; Melissa A Herman; Dean Kirson; Christopher S Oleata; Cristina Irimia; Ilham Polis; Roberto Ciccocioppo; Marisa Roberto; Loren H Parsons
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

Review 4.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

Review 6.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

7.  A common genetic variant in fatty acid amide hydrolase is linked to alterations in fear extinction neural circuitry in a racially diverse, nonclinical sample of adults.

Authors:  Nicole L Zabik; Allesandra S Iadipaolo; Hilary A Marusak; Craig Peters; Kyle Burghardt; Christine A Rabinak
Journal:  J Neurosci Res       Date:  2021-05-29       Impact factor: 4.164

8.  Cannabis as a substitute for prescription drugs - a cross-sectional study.

Authors:  James M Corroon; Laurie K Mischley; Michelle Sexton
Journal:  J Pain Res       Date:  2017-05-02       Impact factor: 3.133

9.  The contributions of the endocannabinoid system and stress on the neural processing of reward stimuli.

Authors:  F M Filbey; D Beaton; S Prashad
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-11-20       Impact factor: 5.067

10.  A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy.

Authors:  Michelle Sexton; Carrie Cuttler; John S Finnell; Laurie K Mischley
Journal:  Cannabis Cannabinoid Res       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.